A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.

Alain Patrick AlgaziJames MoonChristopher D LaoBartosz ChmielowskiKari L KendraKarl D LewisRene GonzalezKevin KimJohn E GodwinBrendan D CurtiMichaella Latkovic-TaberShirley H LomeliBrandon T GuffordPhilip O ScumpiaRoger S LoMegan OthusAntoni Ribas

Published in: Cancer (2024)

Concomitant inhibition of both the MAPK and PI3K-AKT pathways for the treatment of BRAF-mutated cancers was well tolerated, leading to objective responses, but higher level drug-drug interactions affected exposure to dabrafenib and its metabolites.

Keyphrases

pi k akt
signaling pathway
wild type
cell proliferation
metastatic colorectal cancer
cell cycle arrest
ms ms
open label
clinical trial
oxidative stress
young adults
combination therapy
replacement therapy
smoking cessation
childhood cancer